Cyclin‐dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cyclin‐dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer

Published:2019-02-06 Issue:5 Volume:33 Page:5990-6000
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Wang Jinglu¹²,Dean Dylan C.²,Hornicek Francis J.²,Shi Huirong¹,Duan Zhenfeng¹²

Affiliation:

1. Department of Obstetrics and GynecologyThe First Affiliated Hospital of Zhengzhou University Zhengzhou China

2. Department of Orthopaedic SurgeryDavid Geffen School of MedicineUniversity of California‐Los Angeles Los Angeles California USA

Funder

Joint Research Centre

National Natural Science Foundation of China

National Institutes of Health

National Cancer Institute

China Scholarship Council

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201801789RR

Reference46 articles.

1. Cancer statistics, 2018

2. Future options for first-line therapy of advanced ovarian cancer

3. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy

4. Cancer treatment and survivorship statistics, 2016

5. Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK9 inhibitors for the treatment of solid tumors;Biochemical Pharmacology;2024-11

2. Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development;Bioorganic & Medicinal Chemistry Letters;2024-11

3. Expression of cyclin-dependent kinase 9 is positively correlated with the autophagy level in colon cancer;World Journal of Gastrointestinal Oncology;2024-02-15

4. Determination of expression level of AP1S1, CDK9, FIGF and HDAC11 genes in bladder tumors for aggressive phenotype characterization;Biotechnology & Biotechnological Equipment;2023-09-09

5. New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches;Pharmaceuticals;2023-07-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3